SCHEMBL15375646

SCHEMBL15375646

CCNC(=O)C(OCC)c1ccccc1COc1cc(C)ccc1C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SAE1 Q9UBE0 1/20 0.38
UBA2 Q9UBT2 1/20 0.38
POLB P06746 1/20 0.37
LPAR1 Q92633 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7524475 0.90 SMN1; SMN2 (0.44) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL15375490 0.89 TDP1 (0.41) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL15402180 0.85 LMNA (0.42) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL15375431 0.83 LMNA (0.41) LMNAHTTSMN1; SMN2ALDH1A1MEN1
SCHEMBL29365871 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL230669 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL16858325 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL182597 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL29371189 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2
SCHEMBL29368766 0.79 SMN1; SMN2 (0.45) LMNAHTTSMN1; SMN2ALDH1A1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA LMNA 4708/4885HTT 1507/4885SMN1; SMN2 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.